The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer.
Avishay Sella
No relevant relationships to disclose
Tal Sella
No relevant relationships to disclose
Avivit Peer
No relevant relationships to disclose
Raanan Berger
No relevant relationships to disclose
Stephen Jay Frank
No relevant relationships to disclose
Eli Gez
No relevant relationships to disclose
David Sharid
No relevant relationships to disclose
Henry Hayat
No relevant relationships to disclose
Ekaterina Hanovich
No relevant relationships to disclose
Svetlana Kovel
No relevant relationships to disclose
Ekaterina Hanovich
No relevant relationships to disclose
Eli Rosenbaum
Honoraria - Sanofi
Victoria Neiman
No relevant relationships to disclose
Daniel Keizman
No relevant relationships to disclose